What is the Purpose of this Study?
The purpose of this study is to determine how many people from a lung cancer screening program will take part in a study to support magnetic resonance imaging (MRI) and blood-based biomarker research for lung cancer screening. The study aims to support future research that seeks to identify more accurate imaging and blood tests to detect lung cancer at an early stage in people who are at high risk for lung cancer. In this study, researchers will compare MRI characterization of potentially cancerous nodules to low-dose computed tomography (CT) characterization of the same nodules. The study will also utilize a biomarker test to look for genetic material in the blood that can be used to identify early lung cancer. A biomarker is a biological molecule found in blood, other body fluids or tissues that may be a sign of a condition or disease and can be used to predict someone’s response to a specific treatment. Participants will be asked to undergo MRI imaging and provide an optional blood sample, in addition to completing a questionnaire about their MRI experience.
Eligibility
- Ability to read and understand informed consent
- Male or female adults who are at high risk for lung cancer and are enrolled in the centralized lung cancer screening program: Based on USPSTF guidelines: Age 50-80 with 20 or greater pack-year smoking story who continue to smoke or quit within the past 15 years without sign or symptoms of lung cancer. Or based on National Comprehensive Cancer Network (NCCN) guidelines but do not meet the USPSTF guidelines, age 50-unlimited
- Found to have one or more lung nodules that is 6mm or greater on screening LDCT
Where can I participate?
Beverly
More about this Clinical Trial
What is the full name of this clinical trial?
STUDY2249: A Pilot Study Evaluating the Feasibility of Novel MRI Sequences and Blood-Based Biomarkers for Discriminating Cancerous Nodules Found During Lung Cancer Screening *